Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Immix Biopharma ( (IMMX) ) has issued an update.
On June 20, 2025, Immix Biopharma, Inc. held its Annual Meeting where stockholders representing 72.1% of the voting shares were present. During the meeting, the stockholders elected directors to serve until the next annual meeting and ratified the appointment of Crowe LLP as the independent registered public accounting firm for the year ending December 31, 2025.
The most recent analyst rating on (IMMX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 210,574
Technical Sentiment Signal: Buy
Current Market Cap: $62.45M
Learn more about IMMX stock on TipRanks’ Stock Analysis page.